These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 26459536)

  • 1. Evaluation of Xpert(®) MTB/RIF assay: diagnosis and treatment outcomes in rifampicin-resistant tuberculosis.
    Kim YW; Seong MW; Kim TS; Yoo CG; Kim YW; Han SK; Yim JJ
    Int J Tuberc Lung Dis; 2015 Oct; 19(10):1216-21. PubMed ID: 26459536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis in a high HIV prevalence setting.
    Theron G; Peter J; van Zyl-Smit R; Mishra H; Streicher E; Murray S; Dawson R; Whitelaw A; Hoelscher M; Sharma S; Pai M; Warren R; Dheda K
    Am J Respir Crit Care Med; 2011 Jul; 184(1):132-40. PubMed ID: 21493734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systematic screening for drug-resistant tuberculosis with Xpert(®) MTB/RIF in a referral hospital in Cambodia.
    Lorent N; Kong C; Kim T; Sam S; Thai S; Colebunders R; Rigouts L; Lynen L
    Int J Tuberc Lung Dis; 2015 Dec; 19(12):1528-35. PubMed ID: 26614197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Xpert® MTB/RIF assay in routine diagnosis of pulmonary tuberculosis: A multicentre study in Lithuania.
    Pimkina E; Zablockis R; Nikolayevskyy V; Danila E; Davidaviciene E
    Respir Med; 2015 Nov; 109(11):1484-9. PubMed ID: 26403251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Xpert(®) MTB/RIF detection of rifampin resistance and time to treatment initiation in Harare, Zimbabwe.
    Metcalfe JZ; Makumbirofa S; Makamure B; Sandy C; Bara W; Mason P; Hopewell PC
    Int J Tuberc Lung Dis; 2016 Jul; 20(7):882-9. PubMed ID: 27287639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapid and effective diagnosis of tuberculosis and rifampicin resistance with Xpert MTB/RIF assay: a meta-analysis.
    Chang K; Lu W; Wang J; Zhang K; Jia S; Li F; Deng S; Chen M
    J Infect; 2012 Jun; 64(6):580-8. PubMed ID: 22381459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of Xpert MTB/RIF assay in children with presumed pulmonary tuberculosis in Papua New Guinea.
    Kasa Tom S; Welch H; Kilalang C; Tefuarani N; Vince J; Lavu E; Johnson K; Magaye R; Duke T
    Paediatr Int Child Health; 2018 May; 38(2):97-105. PubMed ID: 28490246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of replacing smear microscopy with Xpert MTB/RIF for diagnosing tuberculosis in Brazil: a stepped-wedge cluster-randomized trial.
    Durovni B; Saraceni V; van den Hof S; Trajman A; Cordeiro-Santos M; Cavalcante S; Menezes A; Cobelens F
    PLoS Med; 2014 Dec; 11(12):e1001766. PubMed ID: 25490549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluating the Diagnostic Accuracy of Xpert MTB/RIF Assay in Pulmonary Tuberculosis.
    Sharma SK; Kohli M; Yadav RN; Chaubey J; Bhasin D; Sreenivas V; Sharma R; Singh BK
    PLoS One; 2015; 10(10):e0141011. PubMed ID: 26496123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic accuracy and turnaround time of the Xpert MTB/RIF assay in routine clinical practice.
    Kwak N; Choi SM; Lee J; Park YS; Lee CH; Lee SM; Yoo CG; Kim YW; Han SK; Yim JJ
    PLoS One; 2013; 8(10):e77456. PubMed ID: 24204834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Xpert MTB/RIF on the treatment of multi-drug-resistant or rifampicin-resistant tuberculosis screened out from re-treatment pulmonary tuberculosis patients, a prospective cohort study.
    Wang P; Gu J; Yang J; Yang C; Wu X; Yu F; Fan L
    Ann Palliat Med; 2020 Mar; 9(2):239-246. PubMed ID: 32233619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Performance evaluation of Xpert MTB/RIF in a moderate tuberculosis incidence compared with TaqMan MTB and TRCRapid M.TB.
    Tsuyuguchi K; Nagai H; Ogawa K; Matsumoto T; Morimoto K; Takaki A; Mitarai S
    J Infect Chemother; 2017 Feb; 23(2):101-106. PubMed ID: 27919693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Xpert® MTB/RIF for national tuberculosis programmes in low-income countries: when, where and how?
    Trébucq A; Enarson DA; Chiang CY; Van Deun A; Harries AD; Boillot F; Detjen A; Fujiwara PI; Graham SM; Monedero I; Rusen ID; Rieder HL
    Int J Tuberc Lung Dis; 2011 Dec; 15(12):1567-72. PubMed ID: 22005110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rifampicin Resistance and Multidrug-Resistant Tuberculosis Detection Using Xpert MTB/RIF in Wuhan, China: A Retrospective Study.
    Huang H; Zhang Y; Li S; Wang J; Chen J; Pan Z; Gan H
    Microb Drug Resist; 2018 Jun; 24(5):675-679. PubMed ID: 29053085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of the Xpert MTB/RIF on the detection of pulmonary tuberculosis cases and rifampicin resistance in Shanghai, China.
    Wu Z; Rueda ZV; Li T; Zhang Z; Jiang Y; Sha W; Yu F; Chen J; Pan Q; Shen X; Yuan Z
    BMC Infect Dis; 2020 Feb; 20(1):153. PubMed ID: 32070292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Accuracy of the Xpert® MTB/RIF assay for the diagnosis of extra-pulmonary tuberculosis in South Korea.
    Kim YW; Kwak N; Seong MW; Kim EC; Yoo CG; Kim YW; Han SK; Yim JJ
    Int J Tuberc Lung Dis; 2015 Jan; 19(1):81-6. PubMed ID: 25519795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mixed Mycobacterium tuberculosis complex infections and false-negative results for rifampin resistance by GeneXpert MTB/RIF are associated with poor clinical outcomes.
    Zetola NM; Shin SS; Tumedi KA; Moeti K; Ncube R; Nicol M; Collman RG; Klausner JD; Modongo C
    J Clin Microbiol; 2014 Jul; 52(7):2422-9. PubMed ID: 24789181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the Xpert MTB/RIF assay at a tertiary care referral hospital in a setting where tuberculosis and HIV infection are highly endemic.
    O'Grady J; Bates M; Chilukutu L; Mzyece J; Cheelo B; Chilufya M; Mukonda L; Mumba M; Tembo J; Chomba M; Kapata N; Maeurer M; Rachow A; Clowes P; Hoelscher M; Mwaba P; Zumla A
    Clin Infect Dis; 2012 Nov; 55(9):1171-8. PubMed ID: 22806590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of GeneXpert MTB/RIF® on treatment initiation and outcomes of RIF-resistant and RIF-susceptible TB patients in Vladimir TB dispensary, Russia.
    Ershova JV; Volchenkov GV; Somova TR; Kuznetsova TA; Kaunetis NV; Kaminski D; Demikhova OV; Chernousova LN; Vasilyeva IA; Kerr EM; Cegielski JP; Kurbatova EV
    BMC Infect Dis; 2020 Jul; 20(1):543. PubMed ID: 32711457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of Xpert(®) MTB/RIF assay in the first national anti-tuberculosis drug resistance survey in Pakistan.
    Tahseen S; Qadeer E; Khanzada FM; Rizvi AH; Dean A; Van Deun A; Zignol M
    Int J Tuberc Lung Dis; 2016 Apr; 20(4):448-55. PubMed ID: 26970152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.